More on Vertex Pharmaceuticals (VRTX): Q4 beats consensus estimates, but total revenue dropped...

|About: Vertex Pharmaceuticals Inco... (VRTX)|By:, SA News Editor

More on Vertex Pharmaceuticals (VRTX): Q4 beats consensus estimates, but total revenue dropped by over 38% Y/Y on a plummet in Incivek sales, which came in at $222.8M versus $456.8M the previous year. In December of last year the Hep-C drug was hit by an FDA "Black Box" warning over a potentially fatal skin rash that could occur in patients taking the medication. Shares -2.5% AH.